1.  Liu X.-H., Kirschenbaum A., Yao S., and Levine, A.C. IL-6 and prostaglandin E2 synergistically enhance osteoclastogenesis through effects on the OPG/RANKL/RANK system. Endocrinology 146 (4):1991-1998, 2005. Epub 2004 Dec 23 PubMed PMID: 15618359

2.  Liu X.H., Kirschenbaum A., Yao S., and Levine A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 146(4):1991-8. 2005 Epub 2004 Dec 23. PMID: 15618359

3.  Narla G., DiFeo A., Yao S., Banno A., Hod E., Reeves H.L., Qiao R.F., Camcho-Vanegas O., Levine A.C., Kirschenbaum A., Chan A.M., Friedman S.L. and Marginetti J.A. Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer cell growth and spread. Cancer Research 65(13):5761-5768, 2005. PMID: 15994951

4.  Liu X.H., Kirschenbaum A., Yao S., Aaronson S.A., Liu G. and Levine A.C. Androgen-induced Wnt signaling activation in preosteoblasts promotes the growth of MDA-PCA-2b human prostate cancer cells. Cancer Research 67 (12):5747-53, 2007. PMID: 17575141

5.  Liu XH, Kirschenbaum A, Weinstein BM, Zaidi M, Yao S, Levine AC. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochem Biophys Res Commun.2010 Apr 9;394(3):715-20. Epub 2010 Mar 17. PMID: 20227393

6.  Zaidi M., Li S., Robinson L.J.., Tourkova I.L., Liu L., Wang Y., Ling-Ling Z., Li J., Peng Y., Yang G., Sun H., Levine A., Iqbal J. Yaroslvskiy B.B., Isles, C. and Blair H.C. ACTH protects against glucocorticoid-induced osteonecrosis of bone. PNAS 2010 May 11;107(19):8782-7. Epub 2010 Apr 26. PMCID: PMC2889316 [Available on 2010/11/11